High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster . (20th June 2022)

• Record Type: Journal Article
• Authors: Guirakhoo, Farshad; Wang, Shixia; Wang, Chang Yi; Kuo, Hui Kai; Peng, Wen Jiun; Liu, Hope; Wang, Lixia; Johnson, Marina; Hunt, Adam; Hu, Mei Mei; Monath, Thomas P; Rumyantsev, Alexander; Goldblatt, David
• Is Part Of: Journal of infectious diseases. Volume 226:Number 8(2022)
• Page Start: 1401
• Page End: 1406
• Publication Date: 2022-06-20
• Subjects: SARS-CoV-2 -- COVID-19 -- Omicron -- variant -- subunit -- vaccine -- booster -- receptor-binding domain -- neutralizing antibody -- clinical trial; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac241
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7–9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants. Abstract : A booster dose of UB-612, a next-generation subunit protein-peptide vaccine, induced high cross-reactive antibodies against SARS-CoV-2 variants and is predicted to confer approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral SARS-CoV-2 strain.